

Carbazochrome

Cat. No.:	HY-B1587		
CAS No.:	69-81-8		
Molecular Formula:	C ₁₀ H ₁₂ N ₄ O ₃		
Molecular Weight:	236		
Target:	Adrenergic Receptor		
Pathway:	GPCR/G Protein; Neuronal Signaling		
Storage:	Powder	-20°C	3 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

H₂O : 5 mg/mL (21.19 mM; ultrasonic and adjust pH to 12 with NaOH)

Concentration	Mass		
	1 mg	5 mg	10 mg
1 mM	4.2373 mL	21.1864 mL	42.3729 mL
5 mM	0.8475 mL	4.2373 mL	8.4746 mL
10 mM	0.4237 mL	2.1186 mL	4.2373 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

Carbazochrome is a capillary stabiliser and used for the research of haemorrhage. Carbazochrome is an antihemorrhagic agent^[1].

In Vitro

Carbazochrome (0.1-10 μM) inhibits the Bradykinin induced and thrombin-induced formation of [³H]IP3 in a concentration-dependent manner^[1]. Carbazochrome (0.1-1 μM), when included from 30 min before stimulation, significantly suppressed the enhancement of permeability induced by vasoactive substances^[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Carbazochrome inhibits the severe pulmonary dysfunction induced by the intravenous injection of radiographic contrast media. Carbazochrome (1-10 mg/kg, i.v.) attenuates pulmonary dysfunction induced by a radiographic contrast medium in rats^[2].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Sprague-Dawley rats weighing 180-230 g ^[2]
---------------	------------------------------------------------------------

Dosage:	10 mg/kg
Administration:	I.v.; injected 30, 60, or 90 min before loxaglate injection (4 g l/kg, i.v.).
Result:	Attenuated the loxaglate-increased vascular permeability at the dose of 1, 5 and 10 mg/kg in a dose-dependent manner, achieving statistical significance at 5 and 10 mg/kg.

REFERENCES

- [1]. Toshiaki Sendo, et al. Carbazochrome sodium sulfonate (AC-17) reverses endothelial barrier dysfunction through inhibition of phosphatidylinositol hydrolysis in cultured porcine endothelial cells. *Naunyn Schmiedebergs Arch Pharmacol.* 2003 Sep;368(3):175-80.
- [2]. Toshiaki Sendo, et al. Carbazochrome attenuates pulmonary dysfunction induced by a radiographic contrast medium in rats. *Eur J Pharmacol.* 2002 Aug 23;450(2):203-8.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA